Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo.
This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals
Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Jazz Pharmaceuticals…
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
In the preceding three months, 15 analysts have released ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), presenting a wide array…
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
Providing a diverse range of perspectives from bullish to bearish, 15 analysts have published ratings on Jazz Pharmaceuticals…
The Queen Of Marijuana Investing Used Psychology To Launch Her Successful Cannabis Investment Fund
“Tell me and I forget, teach me and I may remember, involve me and I learn.” Benjamin Franklin…
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program for $10M Upfront Payment and upto $870M Earnout
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat sarcoma virus)